Investors sentiment decreased to 0.98 in 2017 Q2. The biopharmaceutical company reported ($1.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.61) by $0.09. Oppenheimer Asset Management Inc. increased its stake in shares of Sage Therapeutics by 412.9% in the 3rd quarter. 30 funds opened positions while 53 raised stakes. (NASDAQ:SAGE). Tocqueville Asset Mngmt Lp holds 71,450 shares or 0.07% of its portfolio. University Of Notre Dame Du Lac holds 34,936 shares. (NASDAQ:SAGE). Ameritas Investment Prns Inc has invested 0.01% in Sage Therapeutics, Inc. (NASDAQ:SAGE). State Board Of Administration Of Florida Retirement System owns 12,742 shares for 0% of their portfolio. Wexford L P owns 4,400 shares for 0.03% of their portfolio.
The company's shares jumped 52.3 percent to $140 in premarket trading. Suffolk Capital Limited Liability Corporation invested in 0.21% or 20,334 shares. The Massachusetts-based Essex Mngmt Communication Lc has invested 0.36% in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 12,199 shares.
Among 17 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 15 have Buy rating, 0 Sell and 2 Hold. (NASDAQ:SAGE) reached all time high today, Dec, 7 and still has $172.13 target or 7.00 % above today's $160.87 share price. Prelude Mgmt Limited Liability Co holds 0.04% or 5,060 shares. In a report released today, Leerink Swann analyst Paul Matteis reiterated a Buy rating on SAGE.
Sage Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings data on Thursday, November 2nd. It has outperformed by 99.75% the S&P500. If the $172.13 PT is reached, the company will be worth $462.28 million more.
Homelessness Among Families On The Rise In NH
Excluding the Los Angeles region, total homelessness nationwide would have been down by about 1.5 percent compared with 2016. The number of families with children experiencing homelessness declined 8.8 percent since 2016 and 68.7 percent since 2010.
Analysts await Sage Therapeutics, Inc.
SAGE has been the subject of several other research reports. After $-1.97 actual EPS reported by Sage Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 1.52 % negative EPS growth. One analyst has rated the stock with a sell rating, three have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. Therefore 88% are positive. On Thursday, November 9 the stock rating was maintained by Cowen & Co with "Buy". The 12-month average price target assigned to the stock is $116.67, which represents a potential upside of 27% from where the stock is now trading. JP Morgan maintained the shares of SAGE in report on Thursday, September 3 with "Buy" rating. Leerink Swann has "Buy" rating and $9700 target. Raymond James upgraded Sage Therapeutics, Inc. (NASDAQ:SAGE) on Wednesday, June 29 with "Outperform" rating. The rating was maintained by Canaccord Genuity with "Buy" on Monday, November 13. Finally, BlackRock Fund Advisors boosted its position in shares of SAGE Therapeutics by 14.6% in the third quarter.
SAGE-217 was well tolerated, with no serious or severe adverse events; the most common adverse events (AEs) in the SAGE-217 group were headache, dizziness, nausea, and somnolence. "(SAGE) Is Soaring To A New High On Study Results", Cnbc.com published: "Sage Therapeutics shares soar after postpartum depression drug meets main goal" on November 09, 2017. It's hard to understate how meaningful these data are in the backdrop of the very significant unmet medical need in depression: even if the SAGE data on a placebo-adjusted basis weren't differentiated via cross-trial comparisons, we still think '217 would be an important drug as it offers a new mechanism (extra-synaptic GABA-modulation) in an area where the vast majority of options generally modulate the same pathways (serotonin, dopamine, norepinephrine).
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. But back-to-back successes have since then more than doubled the share price, adding billions in market cap. The Company's lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus, as well as for the treatment of post-partum depression (PPD).
Finally, J P Morgan Chase & Co restated a neutral rating on shares of Merck KGaA in a research note on Tuesday, November 28th. The institutional investor owned 1,103,689 shares of the company's stock after selling 7,767 shares during the quarter.
Mundo Deportivo reported on Thursday morning that a deal is already in place for the playmaker to sign a five-year contract. I am at Liverpool and I always do my best when I have the opportunity to play, respecting the jersey and the supporters.
She concluded by writing, "What I learned from Maddie is that fame affects her differently than how it affected me". In her absence, she has relied on others to stand in for her, most notably 15-year-old dancer Maddie Ziegler .
New South Wales Ambulance Superintendent Paul Turner said that because of the circumstances a rescue attempt was incredibly hard . A factory worker has perished in a really horrific manner after getting trapped inside a hot ink tank while cleaning it out.
Amsterdam-based CoolGames is working with Rovio to bring Angry Birds to Messenger's Instant Games platform in early 2018. More information on the live streaming and new games will be coming in the new year when the app updates.
Schroder Investment Management Group owned about 0.45% of Cisco Systems worth $706,583,000 at the end of the most recent quarter. Piper Jaffray maintained Cisco Systems, Inc . (NASDAQ: CSCO ) earned "Positive" rating by OTR Global on Thursday, February 2.
In the piece titled Why Has The #MeToo Revolution Spared Woody Allen? Who Cares If I Liked It? . "It works for Woody Allen still". The choice to boycott, or at least to ignore, anything with his name attached seems perfectly sensible and legitimate.
Mourinho joked Arsenal's medical team had performed an "amazing" feat by turning Lacazette "from a no to a complete 90 minutes". Mourinho was also delighted with the performance with Luke Shaw and Sergio Romero.
West Brom boss Alan Pardew admits he fears losing Jonny Evans next month amid renewed speculation regarding the Albion captain. Evans has featured 13 times for WBA this season, grabbing one goal, and has only missed three league games for the Baggies.
Bayonetta 3 will be a Nintendo Switch exclusive
The Bayonetta Non-Stop Climax Edition will come with a steelbook case, art cards, and other goods for Nintendo Switch. The announcement was made by Reggie who was on stage to reveal the trailer along with Geoff Keighley.
Men director Bryan Singer accused of raping a 17-year-old boy
After the incident, Singer is reported to have both threatened and intimidated Sanchez-Guzman in order to ensure his silence. Bryan Singer , pictured here in 2013, is accused of forcing a then-17-year-old to perform oral sex on him before raping him.
Is Vine Coming Back? V2 Announced By Video App Founder
According to The Verge , Hofmann is now working on another project called Interspace , but is funding V2 independently. But as with any reboot, a recreation of something now canonized has the potential to ruin the reputations of both.
The Bear Case for Ares Capital Corporation (ARCC)
As per Friday, October 6, the company rating was maintained by BMO Capital Markets. 29,187 were accumulated by Cetera Advsrs Ltd. Maltese Capital Management Limited Liability Company stated it has 0.65% in Ares Capital Corporation (NASDAQ: ARCC ).